Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Clin Biochem ; 95: 1-12, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1242901

ABSTRACT

OBJECTIVES: A consensus guidance is provided for testing, utility and verification of SARS-CoV-2 point-of-care test (POCT) performance and implementation of a quality management program, focusing on nucleic acid and antigen targeted technologies. DESIGN AND METHODS: The recommendations are based on current literature and expert opinion from the members of Canadian Society of Clinical Chemists (CSCC), and are intended for use inside or outside of healthcare settings that have varied levels of expertise and experience with POCT. RESULTS AND CONCLUSIONS: Here we discuss sampling requirements, biosafety, SARS-CoV-2 point-of-care testing methodologies (with focus on Health Canada approved tests), test performance and limitations, test selection, testing utility, development and implementation of quality management systems, quality improvement, and medical and scientific oversight.


Subject(s)
COVID-19/diagnosis , Consensus , Point-of-Care Testing/standards , Practice Guidelines as Topic/standards , SARS-CoV-2/isolation & purification , Societies, Scientific/standards , COVID-19/epidemiology , COVID-19/genetics , Canada/epidemiology , Humans , Qualitative Research , Quality Improvement/standards , SARS-CoV-2/genetics
2.
Clin Biochem ; 86: 1-7, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-816352

ABSTRACT

Clinical laboratories across the world are working to validate and perform testing for SARS-CoV-2 antibodies. Herein, we present interim consensus guidance for Canadian clinical laboratories testing and reporting SARS-CoV-2 serology, with emphasis on the capabilities and limitations of these tests and recommendations for interpretative comments in an effort to achieve harmonized laboratory practices. The consensus document provides a broad overview of topics including sample type and contamination risk; kinetics of antibody response to COVID-19 and the impact on serology testing; clinical utility of SARS-CoV-2 serology testing; clinical performance of commercial laboratory-based assays commonly deployed in North America; recommendations for interim reporting; utility of SARS-CoV-2 antibody testing for pediatric patients; and utility of point-of-care testing. The information is based on the current literature and is subject to change as additional information becomes available.


Subject(s)
COVID-19 Serological Testing , COVID-19 , Chemistry, Pharmaceutical , Pandemics , SARS-CoV-2 , Societies, Medical , COVID-19/blood , COVID-19/epidemiology , Canada , Consensus , Humans
SELECTION OF CITATIONS
SEARCH DETAIL